Life Science News

Federal Appellate Court Rejects Controversial J&J Ploy to Dodge Talc Cancer Lawsuits

Nachawati Law Group: Ovarian cancer victims deserve day in court

Trial lawyers with the Nachawati Law Group praised a ruling by the U.S. Court of Appeals for the Third Circuit rejecting Johnson & Johnson's (NYSE: JNJ) use of a controversial bankruptcy ploy to shed more than 38,000 lawsuits filed by women who developed ovarian cancer after using J&J's talc-based products.

The Jan. 30 ruling means J&J can be held accountable for its failure to warn consumers about known cancer risks associated with talc-based products like Johnson's Baby Powder, said trial lawyer Majed Nachawati , founder of Dallas -based Nachawati Law Group.

The Nachawati Law Group represents numerous women who have been diagnosed with ovarian cancer after years of using Johnson's Baby Powder and other talc products produced by the company.

"Our clients are grateful that the appellate court saw through this cynical attempt by J&J to avoid responsibility," said Mr. Nachawati. "We will press forward to ensure that jury trials resume, and these women can have the opportunity for justice they deserve."

In 2021, J&J transferred the lawsuits and jury verdicts to a shell company known as LTL Management. Using a Texas law known as the "Texas Two-Step," LTL briefly incorporated in Texas before quickly filing for bankruptcy. The move sparked controversy because – if successful – it would have allowed a profitable corporation to use bankruptcy law to avoid accountability in the civil justice system.

"It's plain and simple; Profitable corporations like Johnson & Johnson should not be allowed to use bankruptcy laws to avoid accountability," Mr. Nachawati said.

The appellate ruling found that LTL is "highly solvent" and not entitled to file Chapter 11 bankruptcy because J&J had provided it with a $60 billion funding "safety net" to meet its talc liabilities. Judge Thomas Ambro , writing for the appellate panel, said that injured claimants' rights to a jury trial should be "disrupted only when necessary."

With thousands of lawsuits set to resume, Mr. Nachawati said J&J's liability could exceed the $60 billion it had set aside for the LTL bankruptcy.

Nachawati Law Group represents individuals in mass-tort litigation, businesses and governmental entities in contingent litigation, and individual victims in complex personal injury litigation. One of the largest and most diverse products liability law firms in the nation, Nachawati Law Group was ranked No. 1 nationally in products liability filings in federal court over the past three years, according to Lex Machina . For more information visit http://www.ntrial.com/ .

Media Contact:
Robert Tharp
214-420-6011
robert@androvett.com

Cision View original content: https://www.prnewswire.com/news-releases/federal-appellate-court-rejects-controversial-jj-ploy-to-dodge-talc-cancer-lawsuits-301733955.html

SOURCE Nachawati Law Group

News Provided by PR Newswire via QuoteMedia

JNJ
The Conversation (0)

Kaleido Collaborates with Janssen on Metabolic Therapies

Kaleido Biosciences (NADAQ:KLDO) announced a research collaboration with Janssen’s World Without Disease Accelerator, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE:JNJ).

As quoted in the press release:

Keep reading...Show less

XBiotech Sells Human Antibody to Janssen for US$750 Million

XBiotech (NASDAQ:XBIT) announced the closing of the sale of its True Human antibody Bermekimab to Johnson & Johnson’s (NYSE:JNJ) Janssen Biotech.

As quoted in the press release:

Keep reading...Show less
CSE:BOSS

YIELD GROWTH Announces 130 Retail Locations Confirmed to Sell Urban Juve Products

The Yield Growth Corp. (CSE:BOSS, OTCQB:BOSQF, Frankfurt:YG3) is pleased to announce that 130 retail locations across Canada and the US have agreed to sell Urban Juve products with 90 retail locations now live with product. The locations are diverse geographically, and will bring luxury, hemp-powered skincare products to new markets across North America.

Keep reading...Show less

Aduro Biotech Announces Initiation of Phase 1b Clinical Trial in Non-Small Cell Lung Cancer under Janssen Strategic Partnership

Aduro Biotech (NASDAQ:ADRO) announced the recent initiation of a Phase 1b study of ADU-214 (JNJ-64041757) in combination with nivolumab for the treatment of advanced lung cancer. ADU-214 is an immunotherapy based on Aduro’s live, attenuated double-deleted Listeria (LADD) technology platform in development for the treatment of advanced or metastatic non-small cell lung cancer. Janssen Biotech, Inc. (Janssen), Aduro’s license partner for ADU-214, is conducting the global trial.

As quoted in the press release:

Keep reading...Show less

Minerva Neurosciences to Report First Quarter 2016 Financial Results and Business Updates on May 3, 2016

| Source:Minerva Neurosciences, Inc.



WALTHAM, Mass., April 26, 2016 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the first quarter of 2016 on Tuesday, May 3, 2016.  The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.
The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 74086869.  A live webcast of the conference call will be available online in the Investors and Media section of the Company’s website at ir.minervaneurosciences.com.  The archived webcast will be available on the Company’s website beginning approximately two hours after the event for 30 days.
About Minerva Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases.  Minerva’s proprietary compounds include: MIN-101, in Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), which recently completed Phase IIa and Phase Ib clinical trials for insomnia and major depressive disorder (MDD), respectively; MIN-117, in Phase IIa development for MDD; and MIN-301, in pre-clinical development for Parkinson’s disease.  Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.”  For more information, please visit www.minervaneurosciences.com.






Keep reading...Show less

Knight Therapeutics Inc. ranks on The Globe and Mail's fourth-annual Women Lead Here benchmark of executive gender diversity

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company") is pleased to announce it has been included on The Globe and Mail's 2023 Report on Business magazine's Women Lead Here list. This annual editorial benchmark identifies top-notch Canadian businesses with the highest executive gender diversity.

This benchmark was established in 2020 by Report on Business magazine and applies a proprietary research methodology to determine Canadian corporations with the highest degree of gender diversity among executive ranks. The ranking companies have made tangible and organizational progress related to executive gender parity.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

  • TREK-AD Phase 2b study of eblasakimab fully enrolled, topline data readout expected early July 2023
  • Phase 2 proof-of-concept trial of farudodstat in alopecia areata expected to commence in the second quarter of 2023 with topline data readout expected in the first quarter of 2024
  • Expected cash runway extended through at least the second quarter of 2024 with recent $20 million in financing, with potential to receive up an additional $80 million

ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided an update on recent corporate activities.

"We ended 2022 and have begun 2023 achieving a number of milestones across our clinical pipeline that position ASLAN for strong momentum throughout this year and into 2024," said Dr Carl Firth, CEO, ASLAN Pharmaceuticals . "At the end of 2022, we commenced dosing atopic dermatitis (AD) patients in our dupilumab -experienced (TREK-DX) trial. Most notably, we completed enrollment at the start of 2023 in our TREK-AD Phase 2b trial, testing eblasakimab as a novel treatment for moderate-to-severe AD, and we look forward to reporting topline data from this study in early July 2023. In addition, we formed a collaboration with Thermo Fisher Scientific to manufacture a high concentration formulation of eblasakimab that will allow us to administer 400mg in a single subcutaneous injection with a range of different devices."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Medtronic Announces Pricing of $2.0 Billion of Senior Notes

Medtronic plc (the "Company") (NYSE: MDT) announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A. ("Medtronic Luxco"), has priced an offering (the "Offering") of $1,000,000,000 principal amount of 4.25% senior notes due 2028 and $1,000,000 ,000 principal amount of 4.50% senior notes due 2033 (collectively, the "Notes").  All of Medtronic Luxco's obligations under the Notes will be fully and unconditionally guaranteed by the Company and Medtronic, Inc., a wholly-owned indirect subsidiary of Medtronic Luxco, on a senior unsecured basis.

The net proceeds of the Offering are expected to be used to repay indebtedness, which is expected to include a portion of the outstanding indebtedness under Medtronic Luxco's Japanese-yen denominated term loan agreement by and among Medtronic Luxco, the Company, Medtronic, Inc., and Mizuho Bank , Ltd. as administrative agent and as the lender and for general corporate purposes. The Offering is expected to close on March 30, 2023 , subject to customary closing conditions. The joint book-running managers for the Offering are Barclays Capital Inc., J.P. Morgan Securities LLC and Mizuho Securities USA LLC.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Seeking Answers About Transgender Heart Health

Abbott

Abbott

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Don't Mess with Your 'Melon': Abbott and the Brain Injury Association of America Urge 'If You Hit Your Head, Get it Checked' in New Public Service Announcement

  • The Concussion Awareness Now campaign raises awareness both about the common, everyday ways concussions most often happen and the importance of getting concussions evaluated
  • Concussion Awareness Now is a coalition of nearly 20 advocacy groups, founded by Abbott and the Brain Injury Association of America, with Rebel Wilson as the group's inaugural spokesperson
  • The campaign addresses the fact that more than half of people who suspect they have a concussion never get it checked and features a family of characters called the Melons

Concussion Awareness Now, a coalition of nearly 20 advocacy groups founded by Abbott (NYSE: ABT) and the Brain Injury Association of America, unveiled today a new public service campaign to draw attention to concussions and the importance of seeking care.

Experience the interactive Multimedia News Release here: https://www.multivu.com/players/English/9143051-abbott-dont-mess-with-your-melon-the-concussion-awareness-now-campaign/

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Knight Therapeutics Reports Fourth Quarter and Year-End 2022 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading Pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2022. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.

Financial information as at and for the year ended December 31, 2022 is unaudited.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×